<SEC-DOCUMENT>0001193125-19-004095.txt : 20190108
<SEC-HEADER>0001193125-19-004095.hdr.sgml : 20190108
<ACCEPTANCE-DATETIME>20190107213006
ACCESSION NUMBER:		0001193125-19-004095
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190107
FILED AS OF DATE:		20190108
DATE AS OF CHANGE:		20190107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		19514568

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d687583d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated January 7, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION, SERVICE AND SUPPLY AGREEMENT WITH CYTLIMIC</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: January 7, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d687583dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g687583001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION, SERVICE AND SUPPLY AGREEMENT WITH CYTLIMIC </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;)
as part of a cancer peptide vaccine discovered by artificial intelligence </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Builds on Immutep&#146;s longstanding relationship with CYTLIMIC, which recently reported encouraging data in a
Phase I clinical trial with their cancer vaccine product candidate including efti </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150;
7</B><B></B><B>&nbsp;January 2019 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), is pleased to announce that it has entered into a clinical trial collaboration agreement, a supply
agreement and a service agreement with CYTLIMIC Inc. (the &#147;Agreements&#148;) for its lead product candidate eftilagimod alpha as part of a cancer vaccine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine (a therapy containing cancer
antigens to boost a patient&#146;s own immune cells to recognize and kill cancer cells related to the antigens) containing CYTLIMIC&#146;s innovative cancer peptide vaccine, called CYT001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trials will be conducted by and are under the control of CYTLIMIC who will fully fund all development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement, Immutep will receive an upfront payment of US$500,000 and is eligible to receive up to US$4.5M in milestone payments upon
the achievement of milestones by CYTLIMIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This therapeutic cancer vaccine with efti is the third example wherein efti is being evaluated in clinical
studies in a combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep retains complete exclusivity over its patent rights specifically covering its own clinical development programs and
those it is conducting in conjunction with its other collaboration partners evaluating IMP321 in combination with either chemotherapy (AIPAC trial) or <FONT STYLE="white-space:nowrap">PD-1</FONT> / <FONT STYLE="white-space:nowrap">PD-L1</FONT>
immunotherapy (INSIGHT and TACTI trials). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the collaboration agreement, Immutep has entered into a supply agreement to provide efti to
CYTLIMIC for the manufacture of CYT001 for use in the clinical development and commercialisation of the vaccine. The Parties have also entered into a service agreement where Immutep will provide technical support services to CYTLIMIC during the
development and commercialisation of CYT001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the Agreements, Immutep CEO Marc Voigt said: &#147;We are very excited to be working alongside
CYTLIMIC to help evaluate efti as part of an innovative cancer vaccine that has potential as a new therapy. Efti is generating interest globally. Following the agreements with CYTLIMIC, it is now being evaluated as part of three different
combination therapy types: as part of a therapeutic cancer vaccine, as a chemo-immunotherapy and in an IO combination, showing its broad therapeutic potential.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g687583001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the collaboration, CYTLIMIC President and CEO, Shun Doi, Ph.D. said: &#147;We are delighted
with the engagement with Immutep, which will strongly help realize an innovative cancer vaccine-immunotherapy. Our own studies have shown that the combination of <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> and Poly IC synergistically boost the
efficacy of peptide vaccine, and thus I believe the combination of efti in our vaccine CYT001, which is also unique as an application of artificial intelligence, is an important step to add a new solution in cancer immunotherapy world.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CYTLIMIC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CYTLIMIC was established in 2016 by
Japanese multinational NEC Corporation (NEC; TSE: 6701) to promote the development and application of therapeutic cancer peptide vaccines discovered using NEC&#146;s advanced artificial intelligence technology. This technology combines machine
learning and experimentation to produce a unique immune function prediction tool that is able to quickly and efficiently discover peptides that are reactive to multiple HLA alleles. CYTLIMIC also has unique intellectual properties of a combination
of <FONT STYLE="white-space:nowrap">LAG-3</FONT> IgG fusion protein and Poly IC to synergistically boost the effect of peptide vaccine antigens. CYTLIMIC&#146;s current lead product candidate CYT001 is a combination of two <FONT
STYLE="white-space:nowrap">multiple-HLA</FONT> peptides for HSP70 and GPC3 antigens, and <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> (Eftilagimod Alpha) and Poly ICLC (Holtonol) as vaccine adjuvants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for
patients and to maximise value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently
in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive
Immunotherapies) to evaluate a combination of efti with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a planned Phase I clinical
trial referred to as <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel
(clinicaltrials.gov identifier NCT02676869). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Vice President of Business
Development and Investor Relations, Immutep Limited +1 (917) <FONT STYLE="white-space:nowrap">860-9404;</FONT> <U>jay.campbell@immutep.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g687583001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105;
<U>mgregorowski@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garth Russell, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT
STYLE="white-space:nowrap">876-3613;</FONT> <U>garth@lifesciadvisors.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g687583001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g687583001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ :P,T P$1  (1 0,1 ?_$ -D  0 " @(# 0
M       ("08' 04#! H" 0$  @,! 0$             !08!! <# @@0   &
M @ !"P(# P<' A<!   ! @,$!08'$2$2$Y75)E:G"!EI% DQ%19!42)A,B-V
MMG<XD;$DM+47-Z$G<<'14F*2<X.3=#5UI39FAJ979Q@H>#E)$0$   (%"08#
M P@%"@<      0(1 P2D!E,D5 4E919F%R$Q05$2!V%Q$['!%(&1H2(R(Q4V
MT3-S=#7PX?%"4F)R@K)%TF.3LT1D-__:  P# 0 "$0,1 #\ ^_@
M
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MW30\)H>,/!FPV6T
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MHEJ:R:-=Z84T0C-WT0\(=BZE/X<?W\O^47>3Q^<7>H=U/FY'VR
M
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MR$).R,(P\?&,.U:\G\.'[CX?Y!<(0H_*[/+'LH\NQR,OH
M
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M\X!4$_\ >L]45FMV;C^D-:)JFEJYQHK<_N20A"C(R>GQ[.*PDR(N57,(B_<
MECZ8?O,8=LK*:K!M]85"UA/O);-=69O0V<BQPLI\APF6(M]&LFT6F/M//<$?
M4FY(80LRZ0VTD:BQ0>-/BN$S36^ ;-JD56<8O19=4\CK#%O!BSFVE+(EE(AR
M%MF_'6M*B/GM+29E^T>-ILMEM<GT[35R3P^,.U&ZQU/JS6U7"KUA4R5M$>^,
M.WY4^35^+>DGTXX;:M7>/ZDQ2+:QW$NQI<J,]:JBNH/BAV,U;/SF&'$G^"DI
M(R_9^ U:G5.KK/-">IJ9)8P\H?I15DP9ABQ5WUZBQU/U81IA&,*:(_#P2(0T
MELN">0N/'@1$1%^!<G)R$1$)*GLH\(+-1-W1FC1#N[NR'EW/(,,@
M
M                                "#?W$2__ !8SSE/_ ,JX9R?^\M<*
M_B>6'\$KX^/9]L'/O<[U0P?:8PFFAVR]T6A?M3E_S;[3_KU5E_T2.A;+@?\
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M'\M%+]%:DK)J_4UDK)_VOP\G_3! +[$9?TGJ4/\ >K6O#_P>6#92;??WO_\
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MHC,SX\0$X0
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MMZ_W;%B2',7R_$6<'LK-I"E1ZW*,;EV$ROBRG"+F,+LZJR)3)K,B6<=:>7@
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M2:9$%%DEIPC+B2T&1@)@@
M
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M54]A:7(]@UC,!+K4R=$=02VE2GGD-K(E$CG$1D%JA$1<>'[3,SY?VG_F <@
M
M                                           -?["RZ7A\+')4.''F
M+N\[PK$GDR7'&T1XN47T6IDS&^C,C4_%9D&MM)_PJ61$?)Q&(PA&%$>X>/9V
M:+P/#IMW$:B3+V1*K:+%ZR=**)%MLJOYS-50UTF07\3,-R?)2N2XDN<W&0XL
MB_A&8=D*(=S%$*:6N_\ ?5)D:IH<O@5$"5FEUE-3KA6.JL%IJ*[8\O(TXC:U
M\ZS:;>>12U5NT\\;Q-J=>B(2:4\YQ(S",8,P[*:/%GM-D-G11;Q>R\NP'GTK
M<";+E4S,O'X]17V)+1'7>-W-W:G'1(DM+3'>-QI+J4G_  \XC&&(RPBPK9^S
M[O#)&$6U+.Q>QQS++_&Z.+"D0+IZ3;(O[:'"D647+X4K]-8_$KZV84EA4Y!M
MS%HZ)*R6M!'B$(0C3#O9;%V;E,G!M=YKFD&*S.EXMB]S?QH<I;C<>6[5P'I:
M&'UM_P!*AMU37 S3RD030A-WC763;CD8IM;#\,M*J*WB%_BC5G=Y:N6MI6.9
M!=6KM;BD.8RLOIT4MP]7RV%2%+(V99QTGQ2Z9DHA3ZO&#$(0AW,1K_4#?7&O
M-VYK!QB"S(P.2X[@%?8S9+2,JI++'JNUPZUO5):Z6J+(Y,_G\QM*C:B+;5RK
M-1%F'9W,Q[>R-#RK]1#\VSU%6TU EV3E]_&J-E1IDE3;NMENR+;&ORN03:/]
M+O)&=UCL-AM1(2Y%BOO_ ($CB8C+",:8LHOMM6]1B6]<A:J:YV1J:[EU=6RZ
M[(2Q;HC8MB^0I78J3P6RX;]\MH^C_AYB$G^)F,0A"7N*)?*'YG&1;CE8KMUK
M";FGCM8/^E,5LIV:MR5]-1Y%EN09#2T\:[A*1T+&.6#E&3!34K+Z>8\VEPB;
M<YZ480C&F/>>F7R@ZV'N'*L@QO3[6/U-%&S3;;%S-0NV7/=QS&ZO&HJIEY8N
MQXSK-E:R$I=CLQXJ76.D=>-2W4(0KCFDA"$.YDN.9?L"WM,[P*?^E(>=X8UC
M-C%NX\*UD8G=T64HGKKY[E.JR:MZZ>R]33&'HWUCB4K0VXEQ2%\U)E@U=N//
M(6AK'<V4Q\0=<1'BRX=51P+UB/&8+)RH)_UCDF?9RYJB9XO-$RA"N=_#P5^T
M,RK=UUN0YQ?XQC:?KX%'K9S-7)DRLNZB0=B5Q,KFZ[H;:# Z6(IF+SC6V2C)
M7(9ER ,;U9N/(<VU]89U83,6F.L8%$RY-+3XSF5"<";)I7K@Z^59Y(^Y&M8Z
M#;Z'I8B2X\TU_@:0'JZ3WE<[)O:RJD3L'RB)8Z]K\ULK/ /S7H\*M;!=8<7%
M,F1.F6D?ZFRCSGEPUH?;><*$\:F$IYJ@&1X9NP\GV;=X@]#JV,9E'?Q->7T>
MQ2_.R6SP&;'JMA1ID(N+<5$*QFI^@-!F<AB-(6? D$ PFJW[DDW.443:\'N8
M[VW<AUK(P^D.V7GE#44EC85_ZRLG"ES8"H$=N$F3+2[&B-H8=(D.J<)*%AFE
M9M;*)N<HUBY016\R@WS\Z\?24S]/M:I);[U5FT*6I!FY.O%&BL;BFLS;LF9)
MJ(V6N*@JJ^^G_P +M!_WA91_9EH!,3[4W^!G3W_=LW_MQD "Q0
M
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MYG\!<U' N7@ V^
M
M
M
M
M
M
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'_P"I][__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
